# StaphVAX in Cardiovascular Surgery Patients

> **NCT00211913** · PHASE3 · COMPLETED · sponsor: **Nabi Biopharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Staphylococcal Infections
- Cardiovascular Diseases
- Cardiovascular Surgical Procedures

## Interventions

- **BIOLOGICAL:** S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00211913
- **Lead sponsor:** Nabi Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-10
- **Final completion:** 2006-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2008-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211913, "StaphVAX in Cardiovascular Surgery Patients". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00211913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*